VRTX
VRTXXNAS

Vertex Pharmaceuticals Inc

Market cap $121.2B

$477.36

+16.53 (+3.59%)past year

VRTX

$477.36

+0.90% today

Market price$477.36
Shares1
Est. total$477.36

Buy with €1M virtual cash · No real money

Vertex Pharmaceuticals Inc (VRTX) is a publicly traded company listed on the XNAS. As of July 27, 2026, Invest's signal rates VRTX a Hold, with the stock up 0% over the past year. You can practice trading VRTX risk-free with €1,000,000 in virtual cash.

Key stats

As of July 27, 2026

Market Cap

$121.2B

Volume

1.3M

52-wk High

$533.67

52-wk Low

$362.50

Day High

$484.00

Day Low

$472.58

P/E (TTM)

28.33

Revenue (TTM)

$12.2B

EPS (TTM)

$16.85

Performance

1M

+0.5%

6M

+2.1%

1Y

+0.1%

Invest signal · VRTX

Hold
SellHoldBuy
1-year trend+0%
3-month momentum+10%
Valuation (P/E)28.3
Revenue growth (QoQ)-6.4%
Profitability (EPS)Profitable

Algorithmic signal from price trend, valuation, and fundamentals — educational only, not financial advice.

VRTX overview

AI overview

Revenue & EPS — last 8 quarters

QoQ rev -6.4%

Revenue

$3B
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Q1 '26

EPS (diluted)

$4.02 per share
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Q1 '26

About Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults.

Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Employees

6,400

www.vrtx.com

30-Day Win Rate · VRTX

57%WIN RATE
Up days

13 days

Down days

10 days

Last 23 sessions

How to practice trading VRTX

  1. 1

    Use the VRTX buy panel above

    Set a quantity and hit Buy at the real market price — right here, nothing to download.

  2. 2

    Trade with €1,000,000 virtual cash

    You get a million in virtual money instantly to invest, risk-free.

  3. 3

    Create a free account to save it

    Sign up in seconds to keep your portfolio and track its performance.

  4. 4

    Track and compete

    Watch your portfolio grow and climb the global leaderboard — or start a private league.

  5. 5

    Prefer mobile? Get the iOS app

    Invest is also free on the App Store, synced with your web account.

Top VRTX traders on Invest

Full leaderboard
🥇Nora K.+95.0%
🥈james_doyle+86.0%
🥉Julia M.+83.0%
#4noah_b+74.0%
#5Priya S.+65.0%

Frequently asked questions

Is VRTX a good stock to buy right now?

As of July 27, 2026, Invest's signal rates VRTX a Hold, based on its price trend, valuation, and fundamentals (P/E around 28.3), with the stock up 0% over the past year. This is an educational signal, not financial advice — the best way to test the thesis is to practice trading VRTX risk-free first.

What is Vertex Pharmaceuticals Inc's (VRTX) market cap?

Vertex Pharmaceuticals Inc has a market capitalization of approximately $121.2B, on trailing-twelve-month revenue of about $12.2B.

How has VRTX stock performed?

VRTX is up 0% over the past year and up 2% over six months. Its 52-week range runs roughly from $362.50 to $533.67. Past performance doesn't predict future results.

How can I practice trading VRTX for free?

On Invest you get €1,000,000 in virtual cash and can buy VRTX at real market prices right in your browser — no download and no real money at risk. Create a free account to save your portfolio and track its performance over time.

More stocks to practice

Compare VRTX with peers

Invest — Stock Market SimulatorNot financial advice.